Income Taxes (Tables)

12 Months Ended

Dec. 31, 2022

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Schedule of Reconciliation of U.S. Federal Statutory Income Tax Rate

A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:

	Year Ended December 31, 2022			Year Ended December 31, 2021
Federal income tax at statutory rate		21.00	%		21.00	%
Permanent differences		(0.69	)		(0.31	)
Federal and state research and development credits		1.44			2.39
Federal orphan drug credits		7.23			4.51
State income tax, net of federal benefit		5.78			6.12
Impact of ownership change		(2.92	)		—
Other		(0.13	)		(0.06	)
Change in valuation allowance		(31.71	)		(33.65	)
Effective income tax rate		—	%		—	%

Schedule of Deferred Tax Assets and Liabilities

The Company’s deferred tax assets and liabilities consist of the following (in thousands):

	December 31, 2022			December 31, 2021
Deferred tax assets:
Net operating loss carryforwards	$	75,005		$	67,043
Capitalized research and development costs		16,911			—
Orphan drug credit carryforwards		14,628			6,679
Research and development credit carryforwards		10,140			8,774
Intangible assets		6,918			6,192
Accrued expenses and other		5,232			4,537
Operating lease liability		3,613			—
Deferred revenue		251			1,061
Deferred lease incentive		—			832
Deferred rent		—			471
Gross deferred tax assets		132,698			95,589
Valuation allowance		(129,512	)		(94,630	)
Net deferred tax assets		3,186			959
Deferred tax liability		(3,186	)		(959	)
Net deferred tax assets	$	—		$	—